Rhumbline Advisers reduced its position in Zoetis Inc. (NYSE:ZTS) by 1.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,047,264 shares of the company’s stock after selling 18,231 shares during the period. Rhumbline Advisers owned about 0.21% of Zoetis worth $66,774,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in ZTS. Northwestern Mutual Wealth Management Co. grew its stake in Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after acquiring an additional 230 shares during the period. Harfst & Associates Inc. grew its stake in Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after acquiring an additional 260 shares during the period. Almanack Investment Partners LLC. purchased a new stake in Zoetis in the 2nd quarter worth approximately $119,000. Peddock Capital Advisors LLC purchased a new stake in Zoetis in the 2nd quarter worth approximately $140,000. Finally, Parallel Advisors LLC grew its stake in Zoetis by 41.1% in the 2nd quarter. Parallel Advisors LLC now owns 2,263 shares of the company’s stock worth $141,000 after acquiring an additional 659 shares during the period. 92.44% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/11/14/zoetis-inc-zts-holdings-reduced-by-rhumbline-advisers.html.
Zoetis Inc. (NYSE:ZTS) traded down $0.25 during trading hours on Tuesday, hitting $68.88. 2,747,400 shares of the company traded hands, compared to its average volume of 2,817,065. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. The firm has a market cap of $33,686.24, a price-to-earnings ratio of 31.71, a price-to-earnings-growth ratio of 2.02 and a beta of 1.02. Zoetis Inc. has a 1-year low of $48.24 and a 1-year high of $70.48.
Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.02. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.52 EPS. equities research analysts forecast that Zoetis Inc. will post 2.36 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be issued a dividend of $0.105 per share. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 annualized dividend and a dividend yield of 0.61%. Zoetis’s payout ratio is 22.11%.
Several research firms have commented on ZTS. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $62.00 target price on shares of Zoetis in a research note on Monday, August 7th. Morgan Stanley lifted their target price on shares of Zoetis from $61.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Jefferies Group LLC reaffirmed a “buy” rating on shares of Zoetis in a research note on Friday. Cowen and Company set a $70.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, BidaskClub cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 20th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company. Zoetis presently has a consensus rating of “Buy” and a consensus target price of $67.06.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.